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Abstract 
We report the case of a 65-year-old man with recurrent prostate cancer 
presented with meningeal carcinomatosis. 
In September 2007, he was diagnosed with mixed type small cell carcinoma and 
adenocarcinoma at clinical stage T4N1M1 (primary prostate tumor with multiple 
bone, liver, and lymph node metastases) and hormonal therapy was 
administered. Following increase in level of pro-gastrin-releasing peptide 
(ProGRP) combined chemotherapy with cisplatin plus etoposide was 
implemented and showed efficacy in targeting small cell carcinoma. In March 
2008, presenting with signs of meningeal irritation, his condition deteriorated 
quickly and multiple brain metastases were confirmed by magnetic resonance 
imaging (MRI). A sample of cerebrospinal fluid collected by lumbar puncture 
showed cancer cells and elevated level of ProGRP. Small cell carcinoma of the 
prostate complicated with meningeal carcinomatosis was diagnosed. A different 
regimen was then administered consisting of combined chemotherapy of 
carboplatin plus irinotecan, which is one of the most common 1st line treatments 
for extensive stage small cell lung carcinoma. From day 20 after initiation of this 
therapy, he gradually recovered from signs of meningeal irritation, as brain MRI 
showed nearly normal findings, and serum level of ProGRP was improved. 
We report the efficacy of combined treatment with carboplatin plus irinotecan for 
small cell carcinoma of the prostate complicated with meningeal carcinomatosis. 
Because this clinical condition is extremely rare, a gold standard treatment has 
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Introduction 
Small cell carcinoma of the prostate (SCCP) is rare accounting for just 0.5% to 
2% of all prostatic malignant tumors 1. 
In general, clinical features of SCCP include visceral metastases, high incidence 
of osteolytic bone lesions, unresponsiveness to hormone therapy, decreased 
level of serum prostate-specific antigen (PSA), and a high response rate to 
cisplatin plus etoposide chemotherapy 2, 3. 
The prognosis of SCCP is poor with a median survival range of 5 to 17.5 months 
1 and the optimal treatment especially in relapsed chemotherapy treated patients, 
is not clearly established.  
We report a case of refractory relapsed small cell carcinoma of the prostate, 
complicated with meningeal carcinomatosis, in which combined chemotherapy 
with carboplatin plus irinotecan was effective.
Case report 
We report the case of a 65-year-old Japanese man with a history of recurrent 
prostate cancer presented with carcinomatosis. 
At the age of 64 years, he complained of back pain in August 2007 and was 
subsequently hospitalized in September 2007. He reported having smoked 
about 40 cigarettes a day for at least 25 years before the age of 45 and had no 
family history of prostate cancer. Pathological diagnosis using a prostate 
needle biopsy was mixed small cell carcinoma and adenocarcinoma of the 
prostate. The small cell carcinoma showed positive staining for CD56, 
chromogranin A, and synaptophysin and mixed components of adenocarcinoma 
(Gleason Score 4+5=9) (Figure. 1). The clinical stage was T4N1M1 (primary 
prostate tumor with multiple osteolytic bone, liver, lymph node metastases), and 
laboratory values for serum PSA, pro-gastrin-releasing peptide (ProGRP) were 
elevated to 176.77 ng/ml and 544 pg/ml, respectively.  
In September 2007, treatment with dual hormonal therapy using 
gonadotropin-releasing hormone (GnRH) agonist and oral androgen receptor 
antagonist was commenced. His serum PSA levels subsequently became 
undetectable and primary tumor and metastatic lesions showed marked 
shrinkage. However, in October 2007, his serum ProGRP levels increased 
gradually up to 1,660 pg/ml and the primary tumor and metastatic lesions 
expanded. Consequently, the oral androgen receptor antagonist was 
discontinued and he was treated with the GnRH agonist concurrent with cisplatin 
plus etoposide targeting small cell carcinoma. This treatment regimen was 
effective and tumor regression of primary and respective metastatic tumors was 
observed. His serum ProGRP level was decreased to 40.2pg/ml.  
In March 2008, he had a relapse with signs of meningeal irritation, including 
headache, frequent vomiting, and decreased level of consciousness, and he 
deteriorated quickly. In April 2008, he was re-hospitalized. His serum ProGRP 
level had increased again to 1,658 pg/ml; however his level of serum PSA was 
little changed. Magnetic resonance imaging (MRI) revealed multiple brain 
metastases and meningeal carcinomatosis, related with meningeal irritation. A 
lumber puncture was performed to collect a sample of cerebrospinal fluid (CSF) 
for analysis. Atypical cells with high nuclear/cytoplasmic ratio and coarse 
chromatin were detected (Figure. 2) and elevated ProGRP level (4,665 pg/ml) 
was revealed, although the PSA level was undetectable in the sample of CSF 
and a sample of serum. Therefore, small cell carcinoma of prostate, complicated 
with meningeal carcinomatosis was diagnosed. However, time to progression 
was just one month after four cycles of previous combination chemotherapy and 
his performance status was decreased from 1 to 3. We recommended that he 
receive best supportive care, however, he and his family desired other 
treatment.  
In May 2008, we commenced new combined therapy with carboplatin AUC5 
(day1, monthly) plus irinotecan 60mg/m2 (days 1,8 and 15, monthly), which is 
the most common 1st line treatment in patients with extensive-stage small cell 
lung carcinoma. On day 13 after initiation of the therapy, Grade 4 febrile 
neutropenia emerged and he was treated with G-CSF for 5 days and an 
anti-biotic agent for 7 days. His symptoms disappeared by day 20 and his status 
recovered to PS1. Similarly, the multiple brain metastases and meningeal 
carcinomatosis were dramatically diminished in MRI (Figure. 3), and serum 
ProGRP level was decreased to 134.8pg/ml in July 2008. Subsequently, his 
condition was maintained by chemotherapy (irinotecan alone from July 2008 
because of the G4 adverse events) and hormonal therapy for 5 months after the 
induction of 2nd line chemotherapy in May 2008. The clinical course of this case 
is demonstrated in Figure. 4.
Discussion 
Meningeal carcinomatosis in prostate cancer is relatively rare. The incidence 
has been reported as less than 5 % in patients with prostate cancer, particularly 
in those with terminal stage 4. The gold standard for diagnosis of meningeal 
carcinomatosis is dependent on cytological examination of malignant cells in 
CSF. Unfortunately, false-negative results are common, and the positive rate for 
all types of tumors is around 50~60% with one sample, 80% with two, and 90% 
with three 5. However, even multiple CSF samples may fail to yield an accurate 
diagnosis leading to protracted clinical uncertainty for some patients. It has been 
speculated that the cause of false-negative cytology may be the obstruction of 
CSF flow, inadequate amounts of CSF, or delayed handling of cytology 
specimens 6. 
Of imaging methods, gadolinium-enhanced MRI has high sensitivity and 
specificity to abnormal findings with meningeal carcinomatosis, although a 
false-negative rate of up to 30% has been reported 7. In the present case, 
gadolinium-enhanced brain MRI clearly presented enhancement of the meninx 
along the cerebral sulci, and these findings were useful for evaluation of 
abnormal findings and clinical courses. However, imaging methods alone cannot 
render a definitive diagnosis. Therefore, a novel surrogate marker is needed for 
the diagnosis of meningeal carcinomatosis and it is extremely important to define 
the cancer type as well as the presence of any malignancy, e.g. differential 
diagnosis of double primary cancer or mixed type cancer. 
Recently, ProGRP was reported to be a useful and sensitive marker for SCCP as 
well as small cell lung cancer (SCLC) 8. Pedersen et al. demonstrated that 
elevated level of ProGRP in CSF is useful to diagnose meningeal metastases of 
small cell carcinoma 9. Castro MP et al. reported a case with small cell 
carcinoma of unknown primary site, in which the ProGRP level in CSF was 
elevated by more than six orders of magnitude above the serum level despite 
repeated negative CSF cytologic results. Extensive meningeal carcinomatosis 
was demonstrated by autopsy 10. In the present case, the ProGRP level in CSF 
was elevated to 4,665 pg/ml, almost three orders of magnitude above the serum 
level (1658 pg/ml). Thus, diagnosis of meningeal carcinomatosis in patients with 
SCCP may be established by elevated ProGRP levels in CSF samples. To our 
knowledge, this is the first report of SCCP with meningeal carcinomatosis 
monitored by elevated ProGRP level in CSF as well as in serum. 
Hormone therapy for SCCP is ineffective except for mixed type with 
adenocarcinoma 11. Current recommended chemotherapy regimens for SCCP 
are platinum based, similar to SCLC, because SCCP demonstrated similarity to 
SCLC in morphologic features 12 and expression phenotype pattern of some 
genes 13. Of those, combined chemotherapy with cisplatin plus etoposide is the 
most common. A phase II trial of doxorubicin combined with this regimen for 
SCCP showed more toxicity, but not longer survival 2. Other reports showed that 
amrubicin or combination chemotherapy with gemcitabine, docetaxel, and 
carboplatin regimen may be alternative candidates for first induction 
chemotherapy for patients with SCCP 7, 14. 
Chemotherapy has been of limited role in patients with brain metastases 
because of blood brain barrier (BBB). Candidate CNS-acting drugs have the 
poorest success rate and more than 98% of such drugs cannot cross BBB 15. In 
patients with glioma, carboplatin was detectable in CSF beginning 0.5 Hr after 
the initiation of infusion and was then slowly eliminated. The mean maximum 
CSF concentration of carboplatin was 15.25% of that in plasma 16. In preclinical 
studies, irinotecan has demonstrated cytotoxic activity against central nervous 
system tumor xenografts 17. Combined chemotherapy with carboplatin and 
irinotecan was an effective treatment for SCLC brain metastases 18. 
We chose combined chemotherapy with carboplatin plus irinotecan for this 
refractory case with meningeal irritation, in consideration of his poor 
performance status and relapse at only 1 month into treatment with cisplatin and 
etoposide. Fortunately, he responded favorably to treatment and showed 
improved quality of life and performance status. 
In extended disease (ED) of SCLC, cisplatin plus irinotecan was compared with 
cisplatin plus etoposide in a randomized phase III trial and showed a better 
survival rate for patients with good performance status 19. In contrast, carboplatin 
is known to have activity similar to cisplatin but exhibit a more favorable toxicity 
profile and is widely used as a practical substitute for cisplatin in ovarian cancer 
and ED-SCLC. Until now, the combination chemotherapy of carboplatin and 
irinotecan has shown to be a convenient, tolerable, and effective treatment in 
several phase II trials of untreated SCLC in extensive stage 20, 21. In addition, 
high efficacy in carboplatin and irinotecan has been demonstrated in phase II 
trials for refractory or relapsed SCLC patients 22, 23. 
In the present study, we report a rare case of SCCP complicated with meningeal 
carcinomatosis in which combined treatment with carboplatin plus irinotecan was 
effective. Therefore, this combined regimen could be promising for patients with 
relapsed meningeal carcinomatosis with poor performance status or old age.
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Histological findings of a small cell carcinoma component in prostate: Carcinoma 
cells proliferate in solid (left) and trabecular (right) patterns. Carcinoma cells 
have coarse chromatin and dark nuclei. Nuclear/cytoplasmic ratios are high (A). 
Histological findings of an adenocarcinoma component in prostate: Carcinoma 
cells have irregular glandular structures (B). Immunostaining: Synaptophysin is 
diffusely positive for small cell carcinoma (C). A, B, H&E, x400; C, 
Immunostaining of synaptophysin, X200. 
 
Figure 2. 
Cerebrospinal fluid cytology: Cohesive atypical cells with high 
nuclear/cytoplasmic ratio and coarse chromatin are shown. A mitotic figure can 
also be observed in this field. X400  
 
Figure 3.   
Gadolinium-enhanced brain MRI: Multiple brain metastases (arrows) and 
meningeal enhancements due to carcinomatosis (straight arrows) were 
observed in April 2008 (A). However, these findings improved following 
treatment with chemotherapy in August 2008 (B). 
 
Figure 4. 
Clinical course of chemotherapy for small cell carcinoma of the prostate: Trends 
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